Scholarlink

Background <p>A quadrivalent meningococcal tetanus toxoid-conjugate vaccine, MenACYW-TT, was developed to provide broad protection against invasive meningococcal disease across all age groups. We evaluated the immunogenicity and safety of MenACYW-TT as a two-dose series (1 + 1 schedule) co-administered with routine pediatric vaccines to infants from 6 months of age.</p> Methods <p>This phase III modified double-blind, randomized study (NCT03691610) enrolled healthy infants (<i>n</i> = 750) and toddlers (<i>n</i> = 200). Infants were randomized 1:1 to receive MenACYW-TT (Group 1) or another quadrivalent conjugate vaccine, MenACWY-CRM (Group 2) at ages 6–7 and 12–13 months, co-administered with routine vaccines. Toddlers were randomized 1:1 to receive MenACYW-TT (Group 3) or another quadrivalent conjugate vaccine, MenACWY-DT (Group 4) at ages 17–19 and 20–23 months. Functional antibodies against the four meningococcal serogroups were assessed by serum bactericidal antibody assay using human complement (hSBA). Safety was assessed up to 6 months post-vaccination.</p> Results <p>Seroresponse to MenACYW-TT was non-inferior to that with MenACWY-CRM against all four serogroups (seroresponse rates 30 days post-dose 2 were 89.4–99.3% and 82.9–97.7%, respectively). All vaccines were well tolerated.</p> Conclusions <p>These findings support MenACYW-TT administration as a two-dose series in children from 6 months of age.</p> Study registration <p>Clinicaltrials.gov: NCT03691610.</p> Impact <p><UnorderedList Mark="Bullet"> <ItemContent> <p>When administered as a two-dose series (1 + 1 schedule), MenACYW-TT demonstrated comparable/higher immunogenicity to MenACWY-CRM (ages 6–7 and 12–13 months) and the safety profiles of these quadrivalent meningococcal vaccines were similar.</p> </ItemContent> <ItemContent> <p>MenACYW-TT was non-inferior to MenACWY-CRM in terms of seroresponse rates and proportion of participants with antibody titer ≥1:8 after a second dose at age 12–13 months.</p> </ItemContent> <ItemContent> <p>This phase III study is the first to confirm the safety and immunogenicity of MenACYW-TT in infants and supports its use as a two-dose series from 6 months of age.</p> </ItemContent> </UnorderedList></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Meningococcal quadrivalent ACYW-TT conjugated vaccine at 6–23 months: phase III study (US/Puerto Rico)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月6日

查看全文
  • Cheryl Duffy,
  • Olga Lyabis,
  • Mandeep Singh Dhingra,
  • Betzana Zambrano,
  • Julie Chaix,
  • Olga Syrkina,
  • Siham B’Chir,
  • Sandeep Gupta,
  • Christine Rehm

摘要

Background

A quadrivalent meningococcal tetanus toxoid-conjugate vaccine, MenACYW-TT, was developed to provide broad protection against invasive meningococcal disease across all age groups. We evaluated the immunogenicity and safety of MenACYW-TT as a two-dose series (1 + 1 schedule) co-administered with routine pediatric vaccines to infants from 6 months of age.

Methods

This phase III modified double-blind, randomized study (NCT03691610) enrolled healthy infants (n = 750) and toddlers (n = 200). Infants were randomized 1:1 to receive MenACYW-TT (Group 1) or another quadrivalent conjugate vaccine, MenACWY-CRM (Group 2) at ages 6–7 and 12–13 months, co-administered with routine vaccines. Toddlers were randomized 1:1 to receive MenACYW-TT (Group 3) or another quadrivalent conjugate vaccine, MenACWY-DT (Group 4) at ages 17–19 and 20–23 months. Functional antibodies against the four meningococcal serogroups were assessed by serum bactericidal antibody assay using human complement (hSBA). Safety was assessed up to 6 months post-vaccination.

Results

Seroresponse to MenACYW-TT was non-inferior to that with MenACWY-CRM against all four serogroups (seroresponse rates 30 days post-dose 2 were 89.4–99.3% and 82.9–97.7%, respectively). All vaccines were well tolerated.

Conclusions

These findings support MenACYW-TT administration as a two-dose series in children from 6 months of age.

Study registration

Clinicaltrials.gov: NCT03691610.

Impact

When administered as a two-dose series (1 + 1 schedule), MenACYW-TT demonstrated comparable/higher immunogenicity to MenACWY-CRM (ages 6–7 and 12–13 months) and the safety profiles of these quadrivalent meningococcal vaccines were similar.

MenACYW-TT was non-inferior to MenACWY-CRM in terms of seroresponse rates and proportion of participants with antibody titer ≥1:8 after a second dose at age 12–13 months.

This phase III study is the first to confirm the safety and immunogenicity of MenACYW-TT in infants and supports its use as a two-dose series from 6 months of age.